Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria ...

Otsuka licensed rights to Lupkynis in various ex-US markets including the EU, Japan and the UK in 2020, with Aurinia retaining rights to the drug in the US and its home market of Canada.

We are proud to announce that AAA Holding Group has successfully completed the acquisition of an additional 45% stake in the Phosphate Fertiliser Project in Basra, following the purchase of shares ...